newsfilter
← Latest News
Business Wire·

Tempus Study Published in Nature Medicine Demonstrates Best-in-Class Performance of PRISM2 Across Diagnostic and Prognostic Applications

Tempus' multimodal foundation model offers diagnostic-grade precision for cancer detection and unlocks broader applications predicting biomarker status and patient prognosis Tempus AI, Inc. (NASDAQ:TEM), a